Journal
DRUG DELIVERY
Volume 25, Issue 1, Pages 1950-1962Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10717544.2018.1534895
Keywords
Oncolytic virotherapy; herpes simplex virus; envelope glycoprotein; tumor targeting; immune escape; neutralization antibody
Categories
Funding
- National Natural Science Foundation of China [81772223, 81670431, 81602303, 31700736, 81872412]
- Hubei Province Natural Science Foundation of China [2016CFB180]
- Hubei Province Health and Family Planning Scientific Research Project [WJ2016Y07]
- Hubei Province Scientific and Technological Research Project [Q20171306]
- Jingzhou Science and Technology Development Planning Project [JZKJ15063]
- Yangtze University Fellowship
Ask authors/readers for more resources
Oncolytic herpes simplex viruses (oHSVs) have been approved for clinical usage and become more and more popular for tumor virotherapy. However, there are still many issues for the oHSVs used in clinics and clinical trials. The main issues are the limited anti-tumor effects, intratumor injection, and some side effects. To overcome such challenges, here we review the genetic engineering of the envelope glycoproteins for oHSVs to target tumors specifically, and at the same time we summarize the many neutralization antibodies against the envelope glycoproteins and align the neutralization epitopes with functional domains of the respective glycoproteins for future identification of new functions of the glycoproteins and future engineering of the epitopes to escape from host neutralization.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available